I was talking to a prostate cancer patient about the difference between "harm" and "hurt," referring to the Hippocratic Oath. Doctors are ok with "hurting" patients regarding impotence and incontinence, but do all they can to prevent "harm," or death. Both of us agreed this distinction relates to the Hippocratic Oath. But, turns out we [...]
Sign pledge to boycott CVS here: http://bit.ly/2gAJlno CVS Pharmacy will hurt many cancer patients by removing dozens of cancer treatment drugs, like leukemia drug Tasigna, prostate cancer drug Xtandi and chemotherapy treatment drug Neupogen, from their formulary, starting in 2017. CVS claims these drugs cost too much. Go ahead and tell that to my insurance [...]
In a press release issued yesterday, Genomic Health Inc. announced topline results from their clinical validation study of its biopsy-based Oncotype DX® Genomic Prostate Score™ (GPS). The study met its primary endpoint by demonstrating that Oncotype DX® test is a strong predictor for the development of metastasis and also prostate cancer death in men with early-stage prostate [...]
Advanced prostate cancer will eventually end, barring another cause of death, with the demise of the individual survivor. Knowing that you suffer from a terminal illness is hard, it is hard on the family and it is hard on the individual. Many of us don’t think about it, but it is also hard for many [...]
Enzalutamide (Xtandi) has a new, expanded FDA label. The new label conforms with the clinical trial (TERRAIN) results that Xtandi is a superior drug to Casodex (bicalutamide) for men with metastatic castration-resistant prostate cancer (CRPC). The updated product label shows enzalutamide reduces the risk of radiographic progression or death by 40% vs. bicalutamide. Median radiographic [...]